A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

September 24, 2015

Primary Completion Date

January 12, 2018

Study Completion Date

January 12, 2018

Conditions
Huntington's Disease
Interventions
DRUG

Pridopidine

45 mg BID

Trial Locations (46)

1010

Teva Investigational Site 33027, Vienna

2145

Teva Investigational Site 78057, Westmead

3162

Teva Investigational Site 78055, Caulfield South

6005

Teva Investigational Site 78058, West Perth

10032

Teva Investigational Site 12203, New York

10117

Teva Investigational Site 32408, Berlin

11030

Teva Investigational Site 12200, Manhasset

13385

Teva Investigational Site 35124, Marseille

14618

Teva Investigational Site 12198, Rochester

15213

Teva Investigational Site 12209, Pittsburgh

20007

Teva Investigational Site 12196, Washington D.C.

20133

Teva Investigational Site 30080, Milan

21287

Teva Investigational Site 12206, Baltimore

23230

Teva Investigational Site 12210, Richmond

27157

Teva Investigational Site 12211, Winston-Salem

31059

Teva Investigational Site 35165, Toulouse

44791

Teva Investigational Site 32410, Bochum

48149

Teva Investigational Site 32409, Münster

49933

Teva Investigational Site 35123, Angers

50134

Teva Investigational Site 30083, Florence

59037

Teva Investigational Site 35125, Lille

71013

Teva Investigational Site 30081, San Giovanni Rotondo

80054

Teva Investigational Site 35121, Salouël

80113

Teva Investigational Site 12201, Englewood

80131

Teva Investigational Site 30082, Napoli

84108

Teva Investigational Site 12208, Salt Lake City

89081

Teva Investigational Site 32407, Ulm

90095

Teva Investigational Site 12204, Los Angeles

94010

Teva Investigational Site 35122, Créteil

125367

Teva Investigational Site 50213, Moscow

420101

Teva Investigational Site 50215, Kazan'

603126

Teva Investigational Site 50214, Nyznij Novgorod

A-6020

Teva Investigational Site 33021, Innsbruck

M3B 2S7

Teva Investigational Site 11036, Toronto

2333 ZA

Teva Investigational Site 38059, Leiden

80-462

Teva Investigational Site 53150, Gdansk

31-505

Teva Investigational Site 53149, Krakow

60-529

Teva Investigational Site 53148, Poznan

02-957

Teva Investigational Site 53151, Warsaw

B15 2SG

Teva Investigational Site 34058, Birmingham

CB2 2PY

Teva Investigational Site 34054, Cambridge

CF14 4XN

Teva Investigational Site 34059, Cardiff

M13 9WL

Teva Investigational Site 34055, Manchester

NE6 4QD

Teva Investigational Site 34061, Newcastle upon Tyne

OX3 9DU

Teva Investigational Site 34056, Oxford

S10 2JF

Teva Investigational Site 34057, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Prilenia

INDUSTRY